Table 2.
E. coli (%)b | Antimicrobialsa |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Amp | Ot | Sxt | Ct | N | Na | Apr | Cn | Ub | Enr | Amc | |
R | 81.8 | 74 | 45.9 | 41.5 | 48.5 | 49.3 | 33.5 | 31.2 | 31.9 | 30.6 | 42.6 |
I | 9.5 | 8 | 5.3 | 12.2 | 29.1 | 12.8 | 19.3 | 9.6 | 11.1 | 11 | 19 |
S | 8.7 | 18 | 48.7 | 46.3 | 22.2 | 37.7 | 47.1 | 59.1 | 57.2 | 58.3 | 38.3 |
Antimicrobial molecules included in the study: ampicillin (Amp) – 10 μg, oxytetracycline (Ot) – 30 μg, sulphamethoxazole/trimethoprim (Sxt) – 25 μg, colistin (Ct) – 10 μg, neomycin (N) – 30 μg, nalidixic acid (Na) – 30 μg, apramycin (Apr) – 15 μg, gentamicin (Cn) – 10 μg, flumequine (Ub) – 30 μg, enrofloxacin (Enr) – 5 μg and amoxicillin/clavulanic acid (Amc) – 30 μg.
Percentage of resistant (R), intermediate susceptible (I) and susceptible (S) E. coli isolates.